Patients can now access RYALTRIS^® through BlinkRx’s streamlined digital platform as allergy season peaks nationwide

BlinkRx, the digital pharmacy platform designed to make prescription medications more accessible and affordable, today announced that RYALTRIS^® (Olopatadine Hydrochloride and Mometasone Furoate) Nasal Spray, 665 mcg/25 mcg* per spray, is now available for fulfillment through the BlinkRx platform. This follows Glenmark Pharmaceuticals Inc., USA’s transition to direct commercialization and distribution of the product.

As seasonal allergies reach peak levels in many parts of the country, BlinkRx is helping ensure that patients across the United States can access RYALTRIS^® quickly and conveniently.

While RYALTRIS^® is not available through traditional retail pharmacy channels, patients can benefit from a seamless, end-to-end experience through BlinkRx that includes the best available price and free home delivery.

“At BlinkRx, our mission is to ensure that essential medications are easily within reach for everyone. We’re excited to be expanding availability of RYALTRIS^® on our platform during the worst seasonal allergies in many parts of the country,” said Geoff Chaiken, co-founder and CEO of BlinkRx.

“We are pleased to expand access to RYALTRIS^® through BlinkRx, which offers a convenient option for patients,” said Marc Kikuchi, President & Business Head, North America at Glenmark Pharmaceuticals Inc., USA. “As we continue to advance our direct commercialization efforts in the U.S., partnerships like these play a key role in improving how patients access and experience care.”

RYALTRIS^® is indicated for the treatment of symptoms associated with seasonal allergic rhinitis in adult and pediatric patients 12 years of age and older.¹ It is a fixed-dose combination nasal spray that brings together olopatadine hydrochloride (an antihistamine) and mometasone furoate (a corticosteroid) in a single formulation. With demand for allergy relief increasing during the spring season, ensuring reliable and convenient access to effective therapies remains a priority for both providers and patients.

Patients interested in finding out if RYALTRIS^® is right for them should speak with their healthcare provider to learn more. Patients with existing RYALTRIS^® prescriptions can ask their pharmacist to transfer the prescription to BlinkRx.

About BlinkRx
BlinkRx is redefining the pharmacy experience with integrated data-driven technology that improves patient access to branded medications. Its prescription journey management platform streamlines every step of the process, improving the prescription journey across all stakeholders. Patients enjoy the lowest network price, free home delivery, and personalized support. Healthcare providers benefit from dedicated access teams and enhanced prior authorization support for their patients. Pharmacies are able to access technologies that improve their ability to serve patients. And pharmaceutical manufacturers gain greater transparency from prescription to fulfillment. Learn more at www.blinkrx.com.

About Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a global, research‐led, pharmaceutical company with a unique focus on innovation and accessibility. We pioneer transformative breakthrough therapies that aim to redefine treatment while expanding access to high-quality and affordable medicines for patients around the world. With 11 world-class manufacturing facilities across four continents, supported by six cutting-edge R&D centres, and a commercial footprint in 80+ countries, we deliver a diversified portfolio across branded, innovative, generics, and consumer health products, with a focus on respiratory, dermatology, and oncology. Scrip 100 positions Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024. For more information, visit www.glenmarkpharma.com

*Calculated on the anhydrous basis

¹RYALTRIS^® Nasal Spray approved prescribing information, Glenmark Specialty SA, Switzerland.

Please click here to view full prescribing information, including Important Safety Information.

For additional information about RYALTRIS^® and how to access, please visit us.ryaltris.com.

RYALTRIS is a registered trademark of Glenmark Specialty SA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260504424080/en/

Patients can now access RYALTRIS® through BlinkRx’s streamlined digital platform as allergy season peaks nationwide.